We are a computational chemistry and biology CRO helping drug-discovery teams design better
candidates — and the group behind Boltzmann Maps (BMaps).
Company overview
Conifer Point Pharmaceuticals provides computational chemistry and biology services to nonprofit,
academic, and industrial researchers involved in drug discovery and development. We give teams
access to cutting-edge tools and resources — with no need to invest in software, hardware, or a
computational-chemistry hire.
We help increase your success in hit identification, lead qualification, and lead optimization;
accelerate medicinal chemistry projects; and improve the likelihood of grant awards, investment,
and licensing or collaboration opportunities.
Conifer Point Pharmaceuticals has developed and supports Boltzmann Maps,
a web application for drug design that empowers early stage drug discovery. Boltzmann Maps provides
drug researchers with tools to design and prioritize small molecules in pre-clinical drug discovery.
2014
founded in Doylestown, PA
100k+
fragment maps computed
500+
therapeutic targets mapped
$8M+
in research grants awarded
Our lineage
Conifer Point grew out of BioLeap's proprietary fragment-based methods for protein–protein interactions, founded in 2014 by Dr. John L. Kulp III and refined ever since.
History
Key milestones.
A decade of building methods, software, and partnerships in computational drug discovery.
The team at the Pennsylvania Biotechnology Center of Bucks County, Doylestown, PA.
2014
Conifer Point Pharmaceuticals founded as a contract research organization.
2015
Acquired BioLeap assets — fragment-based drug discovery technology and data.
2015
Awarded an NIH grant to develop BMaps, followed by five more grants totaling over $8M.
2017
Initiated long-term CRO deals with EVRYS Bio and FCCDC (annual renewal).
2020
Vibliome and Radius signed long-term deals on the selectivity of their kinase inhibitors.
2020
Surpassed 100,000 fragment maps across 500+ therapeutic targets.
2020
Sold software technology to Lodo Therapeutics (later Zymergen) for $2.0M.
2021
Zymergen engaged Conifer Point on a BMGF grant: natural-product hit identification for six infectious-disease targets.
Our team
Scientists and engineers behind the science.
John Kulp III, PhD
CEO & Founder
Read bio
Daniel Bryan
Chief Software Architect
Read bio
John Kulp Jr., PhD
Chief Technology Officer
Jessica Freeze, PhD
AI Research Scientist III
Read bio
Samuel Bernhard, PhD
Research Scientist III
Read bio
Jacob Chappell, MS
Research Scientist II
Read bio
Ryan Ford
Research Scientist
Andrew Minko
Research Scientist
Richard Bryan
Senior Research Fellow
Mathew Newman
Software Developer
Luz Etcheverry Boneo
Project Manager
Melisa Pardes
Finance & Grants Manager
Work with us
Add a computational engine to your team.
Talk to a chemist about your target — no software, hardware, or comp-chem hire required.
